Exelixis, Inc. (EXEL) is a Biotechnology company in the Healthcare sector, currently trading at $45.86. It has a SharesGrow Score of 83/100, indicating a strong investment profile with 6 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of EXEL = $125.10 (+172.8% from the current price, the stock appears undervalued). Analyst consensus target is EXEL = $44 (-3.8% upside).
Valuation: EXEL trades at a trailing Price-to-Earnings (P/E) of 15.3 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.84.
Financials: revenue is $2.3B, +13%/yr average growth. Net income is $783M, growing at +71.7%/yr. Net profit margin is 33.7% (strong). Gross margin is 96.4% (+0 pp trend).
Balance sheet: total debt is $173M against $2.2B equity (Debt-to-Equity (D/E) ratio 0.08, conservative). Current ratio is 3.56 (strong liquidity). Debt-to-assets is 6.1%. Total assets: $2.8B.
Analyst outlook: 16 / 32 analysts rate EXEL as buy (50%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 74/100 (Pass), Growth 90/100 (Pass), Past 100/100 (Pass), Health 100/100 (Pass), Moat 76/100 (Pass), Future 38/100 (Fail), Income 100/100 (Pass).
